Staff members of Sinovac Biotech, a Chinese biopharmaceutical company, cultivate Vero cells for production of COVID-19 inactivated vaccines in Beijing, capital of China, March 23, 2020. China's National Medical Products Administration (NMPA) on Friday granted conditional market approval to CoronaVac, an inactivated COVID-19 vaccine developed by Sinovac Biotech, the company said on Saturday. The Sinovac vaccine, produced by the Beijing-based Sinovac Life Sciences Co. Ltd., affiliated with Sinovac Biotech, was approved for emergency use in China last June. The vaccine started being used for emergency inoculation among some special groups in the country from July last year. (Xinhua/Zhang Yuwei)
